Joel Greenblatt's VRTX Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 21,511 shares of Vertex Pharmaceuticals Incorporated (VRTX) worth $9.75 M, representing 0.04% of the portfolio. First purchased in 2015-Q4, this long-term strategic position has been held for 36 quarters.
Based on 13F filings, Joel Greenblatt has maintained a strategic position in VRTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2017, adding 182,515 shares. Largest reduction occurred in Q4 2017, reducing 95,516 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Vertex Pharmaceuticals Incorporated (VRTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Vertex Pharmaceuticals Incorporated (VRTX) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -377 | Reduce 1.72% | 21,511 | $453.36 |
| Q3 2025 | +532 | Add 2.49% | 21,888 | $391.64 |
| Q2 2025 | -6,421 | Reduce 23.12% | 21,356 | $445.20 |
| Q1 2025 | -2,334 | Reduce 7.75% | 27,777 | $484.82 |
| Q4 2024 | +2,978 | Add 10.98% | 30,111 | $402.70 |
| Q3 2024 | +2,422 | Add 9.80% | 27,133 | $465.08 |
| Q2 2024 | +6,393 | Add 34.90% | 24,711 | $468.72 |
| Q1 2024 | +1,225 | Add 7.17% | 18,318 | $418.01 |
| Q4 2023 | +4,992 | Add 41.25% | 17,093 | $406.89 |
| Q3 2023 | +648 | Add 5.66% | 12,101 | $347.74 |
| Q2 2023 | -522 | Reduce 4.36% | 11,453 | $351.91 |
| Q1 2023 | -13,765 | Reduce 53.48% | 11,975 | $315.07 |
| Q4 2022 | -11,867 | Reduce 31.56% | 25,740 | $288.78 |
| Q3 2022 | +8,791 | Add 30.51% | 37,607 | $289.55 |
| Q2 2022 | +1,336 | Add 4.86% | 28,816 | $281.79 |
| Q1 2022 | +4,725 | Add 20.76% | 27,480 | $260.95 |
| Q4 2021 | +2,488 | Add 12.28% | 22,755 | $219.60 |
| Q3 2021 | -16,038 | Reduce 44.18% | 20,267 | $181.38 |
| Q2 2021 | +36,305 | New Buy | 36,305 | $201.63 |
| Q4 2020 | -1,527 | Sold Out | 0 | $0.00 |
| Q3 2020 | -8 | Reduce 0.52% | 1,527 | $272.43 |
| Q2 2020 | -447 | Reduce 22.55% | 1,535 | $290.55 |
| Q1 2020 | +845 | Add 74.32% | 1,982 | $238.14 |
| Q4 2019 | -60,130 | Reduce 98.14% | 1,137 | $219.00 |
| Q3 2019 | +59,466 | Add 3301.83% | 61,267 | $169.42 |
| Q2 2019 | +1,801 | New Buy | 1,801 | $183.23 |
| Q2 2018 | -14,974 | Sold Out | 0 | $0.00 |
| Q1 2018 | -10 | Reduce 0.07% | 14,974 | $162.95 |
| Q4 2017 | -95,516 | Reduce 86.44% | 14,984 | $149.89 |
| Q3 2017 | -72,015 | Reduce 39.46% | 110,500 | $152.04 |
| Q2 2017 | +182,515 | New Buy | 182,515 | $128.87 |
| Q4 2016 | -66,716 | Sold Out | 0 | $0.00 |
| Q3 2016 | -41,940 | Reduce 38.60% | 66,716 | $87.21 |
| Q2 2016 | +103,610 | Add 2053.31% | 108,656 | $86.02 |
| Q1 2016 | -6,747 | Reduce 57.21% | 5,046 | $79.47 |
| Q4 2015 | +11,793 | New Buy | 11,793 | $125.84 |
Joel Greenblatt's Vertex Pharmaceuticals Incorporated Investment FAQs
Joel Greenblatt first purchased Vertex Pharmaceuticals Incorporated (VRTX) in Q4 2015, acquiring 11,793 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Vertex Pharmaceuticals Incorporated (VRTX) for 36 quarters since Q4 2015.
Joel Greenblatt's largest addition to Vertex Pharmaceuticals Incorporated (VRTX) was in Q2 2017, adding 182,515 shares worth $23.52 M.
According to the latest 13F filing for Q4 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 21,511 shares of Vertex Pharmaceuticals Incorporated (VRTX), valued at approximately $9.75 M.
As of the Q4 2025 filing, Vertex Pharmaceuticals Incorporated (VRTX) represents approximately 0.04% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in Vertex Pharmaceuticals Incorporated (VRTX) was 182,515 shares, as reported at the end of Q2 2017.